Quantitative information on the so called “three pillars of drug survival” – drug tissue distribution, drug target engagement and post-target pharmacodynamics effects – provides critical information used to optimize dose selection for proof-of-concept studies and kill compounds that will not succeed clinically. While CNS imaging biomarkers have become indispensable in gaining information on the first two pillars, the options for obtaining information on pharmacodynamics, “post-target” effects are more limited. Recent developments provide new opportunities for obtaining robust information on pharmacodynamics effects of a novel drug, using imaging biomarkers. This webinar will review the existing options for such imaging biomarkers.
Ilan is a psychiatrist and psychopharmacologist who was part of the team that set up the GlaxoSmithKline Clinical Imaging Centre, which transitioned to become Imanova in Sep 2011. Ilan spent 10 years at GlaxoSmithKline, and was head of Clinical Imaging Applications at the Translational Medicine and Technologies group.
Ilan received a BSc in Physiology and Medical Biochemistry and a MBBCh, from the University of the Witwatersrand, and specialist training in psychiatry at the University of Cape Town. He was trained in molecular imaging at the MRC Cyclotron Unit, Hammersmith Hospital, London.
Ilan’s research interests focus on the application of molecular imaging to human pathophysiology, psychopharmacology and central nervous system drug development. He is an author of >140 peer reviewed publications.